History

Genveon Pharmaceuticals released its first pharmaceutical product in 2009 in the field of Central Nervous System and introduced many products in various fields of treatment to the service of Turkish medicine since then. Today, it has become one of the key players of the Turkish Pharmaceutical Industry extending its portfolio with value-added original and generic pharmaceutical products in specific fields of treatment such as CNS, Physical Therapy and Rehabilitation/Orthopedics, Infection, Pain and MS.

In 2020, Genveon Pharmaceuticals have incorporated   the Gebze Production Facility which  is considered as the best in its class in Europe and Worldwide where products for 83 countries are being produced with certification given by health authorities in 29 countries.This great investment has enabled Genveon to  contribute  Turkish Pharmaceutical Industry considerably. With this production facility and the ecosystem it has created, Genveon Pharmaceuticals aims to see the outcome of the transformation plan it has created starting from 2021, and thus aims to have a healthy and sustainable growth pursuing a road map that consists of topics such as; becoming a production base for many countries and for the developed countries in particular, increasing its exports, giving value to R&D, and working to create new products.